Table 1.
Participant characteristics of qualitative sample
| Qualitative study participants (n = 29) | |
|---|---|
| Demographics | |
| Mean age in years (SD) | 43.1 (9.8) |
| Gender | |
| Male | 23 (79%) |
| Female | 6 (21%) |
| Transgender | 0 (0%) |
| Ethnicity | |
| Hispanic | 18 (62%) |
| Not Hispanic | 11 (38%) |
| Race | |
| Black | 4 (14%) |
| White | 6 (21%) |
| Multi-racial | 19 (65%) |
| Other groups or refused | 0 |
| Birthplace | |
| United States | 19 (65%) |
| Puerto Rico | 8 (28%) |
| Other | 2 (7%) |
| Socioeconomic factors | |
| Homeless in past 3 months | 16 (55%) |
| Ever incarcerated | 26 (90%) |
| Employment | |
| Unemployed | 25 (86%) |
| Disability | 3 (10%) |
| “Off-books” employment | 1 (3%) |
| Healthcare engagement before study | |
| Aware of HCV diagnosis | 25 (86%) |
| Referred for HCV treatment | 17 (59%) |
| Ever taken HCV treatment | 6 (21%) |
| Seen a doctor in the past 3 months | 21 (72%) |
| Drug treatment in past 3 months (overall)* | 26 (90%) |
| Methadone | 20 (69%) |
| Buprenorphine | 1 (3%) |
| Residential treatment | 10 (34%) |
| Study outcomes | |
| Initiated treatment | 29 (100%) |
| Completed treatment | 27 (93%) |
| Achieved SVR12** | 27 (93%) |
SVR12 sustained virologic response at 12 weeks
*Total does not sum to 29 because participants could receive multiple forms of drug treatment in past 90 days. **3 participants did not achieve SVR12 during initial treatment but did so after re-treatment while still engaged in the study